Shanghai Kaibao PharmaceuticalLtd Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yingbin Zhou
Chief executive officer
CN¥461.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.3yrs |
CEO
Yingbin Zhou (47 yo)
Mr. Yingbin Zhou was Deputy GM of Shanghai Kaibao Pharmaceutical CO. Ltd. Mr. Zhou was Non-Independent Director of Shanghai Kaibao Pharmaceutical CO.Ltd from December 10, 2020. Mr. Yingbin Zhou is GM & Di...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 2.3yrs | CN¥461.30k | no data | |
| Deputy GM & Non-Independent Director | 2.3yrs | CN¥472.60k | no data | |
| Board Secretary & Non-Independent Director | 17.7yrs | CN¥309.50k | 0.16% CN¥ 9.8m | |
| Deputy General Manager | 2.4yrs | CN¥240.60k | 0.018% CN¥ 1.1m | |
| Financial Director | 1.7yrs | no data | no data | |
| Accounting Supervisor | no data | no data | no data |
Experienced Management: 300039's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 8.4yrs | CN¥461.30k | no data | |
| Deputy GM & Non-Independent Director | 2.3yrs | CN¥472.60k | no data | |
| Board Secretary & Non-Independent Director | 2.3yrs | CN¥309.50k | 0.16% CN¥ 9.8m | |
| Non Independent Director | 1.8yrs | CN¥312.00k | 0.22% CN¥ 13.6m | |
| Chairman | 11.4yrs | CN¥761.00k | 16.06% CN¥ 1.0b | |
| Chairman of the Supervisory Board | 2.3yrs | CN¥344.30k | no data | |
| Shareholder Representing Supervisor | 8.4yrs | no data | no data | |
| Independent Director | 5.3yrs | CN¥75.00k | no data | |
| Independent Director | 5.3yrs | CN¥75.00k | no data | |
| Independent Director | 2.3yrs | CN¥75.00k | no data | |
| Non-Independent Director | 2.3yrs | CN¥323.40k | no data |
Experienced Board: 300039's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 08:53 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Kaibao Pharmaceutical CO.,Ltd is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chao Li | Citic Securities Co., Ltd. |
| Jie Yao | Everbright Securities Co. Ltd. |
| Weina Jiang | Everbright Securities Co. Ltd. |